The Phoenix platform utilizes genetically similar matches to predict effective interventions for users.

SINGAPORE, July 18, 2025 — Phoenix today introduced the alpha version of its app employing “digital twin” technology. This app assists APOE4 carriers—1.1 billion individuals globally with a significantly increased risk (up to 33x) of developing Alzheimer’s—in discovering personalized and effective protocols tailored to their unique genetic makeup.

The APOE4 gene, present in 25% of the population, contributes to 44% of all Alzheimer’s cases, resulting in an annual cost of $181 billion in the U.S. With 1.1 billion carriers worldwide facing substantially elevated risk, personalized solutions are critically needed.

Your Genetic Doppelganger Holds the Answers

The Phoenix app analyzes over 50 biomarkers to pair users with “digital twins”—other APOE4 carriers sharing similar genetic, age, and health characteristics. It then forecasts the success of interventions based on the actual outcomes observed in these genetically similar matches.

“APOE4 carriers are often simply advised to ‘eat healthy and exercise’ despite facing a risk of Alzheimer’s that’s up to 33 times higher. This is akin to telling someone in a burning building to remain calm,” stated Dr. Kevin Tran, founder of Phoenix and an APOE4 homozygote. “We couldn’t afford to wait decades for trial results. Therefore, we created the world’s first continuous experiment network, where data from every member contributes to unraveling the code.”

.

APOE4-Specific Blood Analysis: The Phoenix Score assesses over 50 biomarkers using ranges optimized for APOE4 carriers to identify hidden risks. For example, while standard ApoB levels may appear “normal,” APOE4 carriers require levels below 70 mg/dL. The dashboard offers specific actionable steps.

.

Evidence-Based APOE4 Protocols: Features 20+ interventions specifically validated for APOE4 carriers. Each intervention includes a difficulty rating, time commitment, required testing, and step-by-step implementation guides derived from the outcomes of genetic twins.

The platform has gained significant traction:

  • Supported by leading global Alzheimer’s and APOE4 researchers.
  • Over 950 APOE4 carriers have joined in just 4 months, with monthly growth doubling.
  • “Exactly what my APOE4 patients needed,” a neurologist reports.
  • Endorsed by APOE4.info, the largest APOE4 nonprofit worldwide.

Secure lifetime Founding Member access at [website address]—available for a limited time.

About Phoenix: A science-based community dedicated to helping APOE4 carriers overcome the odds and proactively combat Alzheimer’s.

Contact:
Dr. Kevin Tran
Phone number: +65 8429 9341
Email: [email protected]
Website: [website address]

Disclaimer: This content is provided by Phoenix. The statements, views, and opinions expressed are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only and should not be considered financial, investment, or business advice. All investments carry inherent risks, including the potential loss of capital. Readers are strongly encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Neither the media platform nor the publisher shall be held responsible for any inaccuracies, misrepresentations, or financial losses resulting from the use or reliance on the information in this press release. Speculate only with funds you can afford to lose. In the event of any legal claims or concerns regarding this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.

Legal Disclaimer: This media platform provides the content of this article on an “as-is” basis, without warranties or representations of any kind, express or implied. We assume no responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained herein. Any complaints, copyright issues, or inquiries regarding this article should be directed to the content provider listed above.

Photos accompanying this announcement are available at [photo link]

“`